References
- Terwilliger T, Abdul-Hay M. Acute lymphoblastic leukemia: a comprehensive review and 2017 update. Blood Cancer J. 2017;7(6):e577. doi:https://doi.org/10.1038/bcj.2017.53
- Iacobucci I, Mullighan CG. Genetic basis of acute lymphoblastic leukemia. J Clin Oncol. 2017;35(9):975–983. doi:https://doi.org/10.1200/JCO.2016.70.7836
- Mohseni M, Uludağ H, Brandwein JM. Advances in biology of acute lymphoblastic leukemia (ALL) and therapeutic implications. Am J Blood Res. 2018;8:29–56.
- Liu-Dumlao T, Kantarjian H, Thomas DA, O’Brien S, Ravandi F. Philadelphia-positive acute lymphoblastic leukemia: current treatment options. Curr Oncol Rep. 2012;14(5):387–394. doi:https://doi.org/10.1007/s11912-012-0247-7
- Abou Dalle I, Jabbour E, Short NJ, Ravandi F. Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia. Curr Treat Options Oncol. 2019;20(1):4. doi:https://doi.org/10.1007/s11864-019-0603-z
- Hannun YA, Obeid LM. Sphingolipids and their metabolism in physiology and disease. Nat Rev Mol Cell Biol. 2018;19(3):175–191. doi:https://doi.org/10.1038/nrm.2017.107
- Ogretmen B. Sphingolipid metabolism in cancer signalling and therapy. Nat Rev Cancer. 2018;18(1):33–50. doi:https://doi.org/10.1038/nrc.2017.96
- Sala G, Minutolo F, Macchia M, Sacchi N, Ghidoni R. Resveratrol structure and ceramide-associated growth inhibition in prostate cancer cells. Drugs Exp Clin Res. 2003;29(5–6):263–269.
- Senchenkov A, Litvak DA, Cabot MC. Targeting ceramide metabolism-a strategy for overcoming drug resistance. J Natl Cancer Inst. 2001;93(5):347–357. doi:https://doi.org/10.1093/jnci/93.5.347
- Hannun YA, Obeid LM. Principles of bioactive lipid signalling: lessons from sphingolipids. Nat Rev Mol Cell Biol. 2008;9(2):139–150. doi:https://doi.org/10.1038/nrm2329
- Baran Y, Salas A, Senkal CE, Gunduz U, Bielawski J, Obeid LM, Ogretmen B. Alterations of ceramide/sphingosine 1-phosphate rheostat involved in the regulation of resistance to imatinib-induced apoptosis in K562 human chronic myeloid leukemia cells. J Biol Chem. 2007;282(15):10922–10934. doi:https://doi.org/10.1074/jbc.M610157200
- Jafari N, Drury J, Morris AJ, Onono FO, Stevens PD, Gao T, Liu J, Wang C, Lee EY, Weiss HL, et al. De novo fatty acid synthesis-driven sphingolipid metabolism promotes metastatic potential of colorectal cancer. Mol Cancer Res. 2019;17(1):140–152. doi:https://doi.org/10.1158/1541-7786.MCR-18-0199
- Abuhusain HJ, Matin A, Qiao Q, Shen H, Kain N, Day BW, Stringer BW, Daniels B, Laaksonen MA, Teo C, et al. A metabolic shift favoring sphingosine 1-phosphate at the expense of ceramide controls glioblastoma angiogenesis. J Biol Chem. 2013;288(52):37355–37364. doi:https://doi.org/10.1074/jbc.M113.494740
- Berman AY, Motechin RA, Wiesenfeld MY, Holz MK. The therapeutic potential of resveratrol: a review of clinical trials. NPJ Precis Oncol. 2017;1:35.
- Gatz SA, Wiesmuller L. Take a break-resveratrol in action on DNA. Carcinogenesis. 2008;29(2):321–332. doi:https://doi.org/10.1093/carcin/bgm276
- Parekh P, Motiwale L, Naik N, Rao KVK. Downregulation of cyclin D1 is associated with decreased levels of p38 MAP kinases, Akt/PKB and Pak1 during chemopreventive effects of resveratrol in liver cancer cells. Exp Toxicol Pathol. 2011;63(1–2):167–173. doi:https://doi.org/10.1016/j.etp.2009.11.005
- Jazirehi AR, Bonavida B. Resveratrol modifies the expression of apoptotic regulatory proteins and sensitizes non-Hodgkin’s lymphoma and multiple myeloma cell lines to paclitaxel-induced apoptosis. Mol Cancer Ther. 2004;3(1):71–84.
- AdanGokbulut A, Apohan E, Baran Y. Resveratrol and quercetin-induced apoptosis of human 232b4 chronic lymphocytic leukemia cells by activation of caspase-3 and cell cycle arrest. Hematology. 2013;18(3):144–150. doi:https://doi.org/10.1179/1607845412Y.0000000042
- Dei Cas M, Ghidoni R. Cancer prevention and therapy with polyphenols: sphingolipid-mediated mechanisms. Nutrients. 2018;10(7):940. doi:https://doi.org/10.3390/nu10070940
- Mizutani N, Omori Y, Kawamoto Y, Sobue S, Ichihara M, Suzuki M, Kyogashima M, Nakamura M, Tamiya-Koizumi K, Nozawa Y, et al. Resveratrol-induced transcriptional up-regulation of ASMase (SMPD1) of human leukemia and cancer cells. Biochem Biophys Res Commun. 2016;470(4):851–856. doi:https://doi.org/10.1016/j.bbrc.2016.01.134
- Shin K-O, Park N-Y, Seo C-H, Hong S-P, Oh K-W, Hong J-T, Han S-K, Lee Y-M. Inhibition of sphingolipid metabolism enhances resveratrol chemotherapy in human gastric cancer cells. Biomol Ther. 2012;20(5):470–476. doi:https://doi.org/10.4062/biomolther.2012.20.5.470
- Chow S-E, Kao C-H, Liu Y-TA, Cheng M-L, Yang Y-W, Huang Y-K, Hsu C-C, Wang J-S. Resveratrol induced ER expansion and ER caspase-mediated apoptosis in human nasopharyngeal carcinoma cells. Apoptosis. 2014;19(3):527–541. doi:https://doi.org/10.1007/s10495-013-0945-0
- Adan A, Baran Y. The pleiotropic effects of fisetin and hesperetin on human acute promyelocytic leukemia cells are mediated through apoptosis, cell cycle arrest, and alterations in signaling networks. Tumour Biol. 2015;36(11):8973–8984. doi:https://doi.org/10.1007/s13277-015-3597-6
- Athar M, Back JH, Kopelovich L, Bickers DR, Kim AL. Multiple molecular targets of resveratrol: anti-carcinogenic mechanisms. Arch Biochem Biophys. 2009;486(2):95–102. doi:https://doi.org/10.1016/j.abb.2009.01.018
- Wang M, Yu T, Zhu C, Sun H, Qiu Y, Zhu X, Li J. Resveratrol triggers protective autophagy through the ceramide/Akt/mTOR pathway in melanoma B16 cells. Nutr Cancer. 2014;66(3):435–440. doi:https://doi.org/10.1080/01635581.2013.878738
- Scarlatti F, Sala G, Somenzi G, Signorelli P, Sacchi N, Ghidoni R. Resveratrol induces growth inhibition and apoptosis in metastatic breast cancer cells via de novo ceramide signaling. FASEB J. 2003;17(15):2339–2341. doi:https://doi.org/10.1096/fj.03-0292fje
- Kartal M, Saydam G, Sahin F, Baran Y. Resveratrol triggers apoptosis through regulating ceramide metabolizing genes in human K562 chronic myeloid leukemia cells. Nutr Cancer. 2011;63(4):637–644. doi:https://doi.org/10.1080/01635581.2011.538485
- Liu Z, Wu X, Lv J, Sun H, Zhou F. Resveratrol induces p53 in colorectal cancer through SET7/9. Oncol Lett. 2019;17(4):3783–3789. doi:https://doi.org/10.3892/ol.2019.10034
- Siedlecka-Kroplewska K, Wozniak M, Kmiec Z. The wine polyphenol resveratrol modulates autophagy and induces apoptosis in MOLT-4 and HL-60 human leukemia cells. J Physiol Pharmacol. 2019;70:825–838.
- Wang B, Liu J, Gong Z. Resveratrol induces apoptosis in K562 cells via the regulation of mitochondrial signaling pathways. Int J Clin Exp Med. 2015;8(9):16926–16933.
- Newton J, Lima S, Maceyka M, Spiegel S. Revisiting the sphingolipid rheostat: evolving concepts in cancer therapy. Exp Cell Res. 2015;333(2):195–200. doi:https://doi.org/10.1016/j.yexcr.2015.02.025
- Lim KG, Gray AI, Pyne S, Pyne NJ. Resveratrol dimers are novel sphingosine kinase 1 inhibitors and affect sphingosine kinase 1 expression and cancer cell growth and survival. Br J Pharmacol. 2012;166(5):1605–1616. doi:https://doi.org/10.1111/j.1476-5381.2012.01862.x
- Lin H-Y, Delmas D, Vang O, Hsieh T-C, Lin S, Cheng G-Y, Chiang H-L, Chen CE, Tang H-Y, Crawford DR, et al. Mechanisms of ceramide-induced COX-2-dependent apoptosis in human ovarian cancer OVCAR-3 cells partially overlapped with resveratrol. J Cell Biochem. 2013;114(8):1940–1954. doi:https://doi.org/10.1002/jcb.24539
- Tian H, Yu Z. Resveratrol induces apoptosis of leukemia cell line K562 by modulation of sphingosine kinase-1 pathway. Int J Clin Exp Pathol. 2015;8(3):2755–2762.
- Cakir Z, Saydam G, Sahin F, Baran Y. The roles of bioactive sphingolipids in resveratrol-induced apoptosis in HL60: acute myeloid leukemia cells. J Cancer Res Clin Oncol. 2011;137(2):279–286. doi:https://doi.org/10.1007/s00432-010-0884-x
- Xie V, Tong D, Wallington-Beddoe CT, Bradstock KF, Bendall LJ. Sphingosine kinase 2 supports the development of BCR/ABL-independent acute lymphoblastic leukemia in mice. Biomark Res. 2018;6(6):6. doi:https://doi.org/10.1186/s40364-018-0120-4